Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong Won Lee, Keun Seok Lee, Joohyuk SohnKyung Hae Jung, In Hae Park

Research output: Contribution to journalArticlepeer-review

Abstract

We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

Original languageEnglish
Pages (from-to)172-178
Number of pages7
JournalBreast
Volume65
DOIs
StatePublished - Oct 2022

Keywords

  • Clinical trial
  • ctDNA
  • HER2 positive
  • Metastatic breast cancer
  • Trastuzumab biosimilar

Fingerprint

Dive into the research topics of 'Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)'. Together they form a unique fingerprint.

Cite this